JP2023521604A5 - - Google Patents

Info

Publication number
JP2023521604A5
JP2023521604A5 JP2022559557A JP2022559557A JP2023521604A5 JP 2023521604 A5 JP2023521604 A5 JP 2023521604A5 JP 2022559557 A JP2022559557 A JP 2022559557A JP 2022559557 A JP2022559557 A JP 2022559557A JP 2023521604 A5 JP2023521604 A5 JP 2023521604A5
Authority
JP
Japan
Prior art keywords
nucleotide
nucleotides
mapt
dsrna agent
antisense
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022559557A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023521604A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/024858 external-priority patent/WO2021202511A2/en
Publication of JP2023521604A publication Critical patent/JP2023521604A/ja
Publication of JP2023521604A5 publication Critical patent/JP2023521604A5/ja
Priority to JP2026032134A priority Critical patent/JP2026116278A/ja
Pending legal-status Critical Current

Links

JP2022559557A 2020-03-30 2021-03-30 微小管関連タンパク質タウ(MAPT)iRNA剤組成物およびその使用方法 Pending JP2023521604A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026032134A JP2026116278A (ja) 2020-03-30 2026-03-02 微小管関連タンパク質タウ(MAPT)iRNA剤組成物およびその使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063002030P 2020-03-30 2020-03-30
US63/002,030 2020-03-30
US202163164467P 2021-03-22 2021-03-22
US63/164,467 2021-03-22
PCT/US2021/024858 WO2021202511A2 (en) 2020-03-30 2021-03-30 MICROTUBULE ASSOCIATED PROTEIN TAU (MAPT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026032134A Division JP2026116278A (ja) 2020-03-30 2026-03-02 微小管関連タンパク質タウ(MAPT)iRNA剤組成物およびその使用方法

Publications (2)

Publication Number Publication Date
JP2023521604A JP2023521604A (ja) 2023-05-25
JP2023521604A5 true JP2023521604A5 (cg-RX-API-DMAC7.html) 2024-04-10

Family

ID=77929772

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022559557A Pending JP2023521604A (ja) 2020-03-30 2021-03-30 微小管関連タンパク質タウ(MAPT)iRNA剤組成物およびその使用方法
JP2026032134A Pending JP2026116278A (ja) 2020-03-30 2026-03-02 微小管関連タンパク質タウ(MAPT)iRNA剤組成物およびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026032134A Pending JP2026116278A (ja) 2020-03-30 2026-03-02 微小管関連タンパク質タウ(MAPT)iRNA剤組成物およびその使用方法

Country Status (12)

Country Link
US (1) US20230203486A1 (cg-RX-API-DMAC7.html)
EP (1) EP4126230A4 (cg-RX-API-DMAC7.html)
JP (2) JP2023521604A (cg-RX-API-DMAC7.html)
KR (1) KR20230005194A (cg-RX-API-DMAC7.html)
CN (1) CN116234585A (cg-RX-API-DMAC7.html)
AU (1) AU2021246024A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022019606A2 (cg-RX-API-DMAC7.html)
CA (1) CA3178304A1 (cg-RX-API-DMAC7.html)
IL (1) IL296851A (cg-RX-API-DMAC7.html)
MX (1) MX2022012293A (cg-RX-API-DMAC7.html)
TW (1) TW202143984A (cg-RX-API-DMAC7.html)
WO (1) WO2021202511A2 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240067943A (ko) * 2021-09-24 2024-05-17 알닐람 파마슈티칼스 인코포레이티드 미소관 연관 단백질 타우(MAPT) iRNA 제제 조성물 및 이의 사용 방법
US20250340872A1 (en) * 2021-10-07 2025-11-06 Ionis Pharmaceuticals, Inc. Compounds and methods for reducing tau expression
MX2024007056A (es) 2021-12-13 2024-06-24 Lilly Co Eli Agentes de interferencia de arn de mapt.
US20250171777A1 (en) 2022-02-11 2025-05-29 Alnylam Pharmaceuticals, Inc. Microtubule Associated Protein Tau (MAPT) iRNA Agent Compositions and Methods of Use Thereof
KR20240154674A (ko) * 2022-03-16 2024-10-25 얀센 파마슈티카 엔브이 MAPT siRNA 및 이의 용도
WO2024145474A2 (en) * 2022-12-29 2024-07-04 Voyager Therapeutics, Inc. Compositions and methods for regulating mapt
WO2024201423A2 (en) * 2023-03-30 2024-10-03 Biorchestra Co., Ltd. Microtubule-associated protein tau targeting sirnas and uses thereof
EP4698652A2 (en) * 2023-04-20 2026-02-25 Adarx Pharmaceuticals, Inc. Mapt-modulating compositions and methods of use thereof
KR20260046111A (ko) * 2023-08-01 2026-04-06 투오지에 바이오텍 (상하이) 컴퍼니 리미티드 MAPT를 표적으로 하는 dsRNA 및 이의 의약적 용도
EP4754256A1 (en) * 2023-08-02 2026-06-10 Consejo Nacional de Investigaciones Científicas Y Técnicas (CONICET) Micrornas designed against the microtubule-associated protein tau for the treatment of tauopathies
KR20260085142A (ko) * 2023-10-11 2026-06-08 상하이 아르고 바이오파마슈티칼 씨오., 엘티디. 미세소관 관련 단백질 tau(mapt)의 발현을 억제하기 위한 조성물 및 방법
WO2025212467A1 (en) * 2024-03-31 2025-10-09 Arrowhead Pharmaceuticals, Inc. Rnai agents for inhibiting expression of microtubule associated protein tau (mapt), compositions thereof, and methods of use
WO2025233849A2 (en) * 2024-05-07 2025-11-13 Janssen Pharmaceutica Nv MAPT siRNA AND USES THEREOF
WO2026010722A1 (en) * 2024-07-03 2026-01-08 Voyager Therapeutics, Inc. Compositions and methods for regulating mapt
WO2026017176A1 (zh) * 2024-07-19 2026-01-22 北京安龙生物医药有限公司 靶向微管相关蛋白Tau基因的寡核苷酸及其用途
CN121780524A (zh) * 2024-08-02 2026-04-03 北京尧景基因技术有限公司 抑制MAPT基因表达的siRNA及其缀合物和应用
WO2026026982A1 (zh) * 2024-08-02 2026-02-05 成都先衍生物技术有限公司 一种靶向MAPT基因表达的siRNA及其缀合物和用途
US20260167963A1 (en) * 2024-08-29 2026-06-18 Synerk Inc. Compounds, Compositions and Methods for Reducing MAPT (TAU) Expression
WO2026067655A1 (zh) * 2024-09-26 2026-04-02 大睿生物医药科技(上海)有限公司 调控TAU表达的dsRNA分子
WO2026085233A1 (en) * 2024-10-16 2026-04-23 Alnylam Pharmaceuticals, Inc. MICROTUBULE ASSOCIATED PROTEIN TAU (MAPT) iRNA FORMULATIONS AND METHODS OF USE THEREOF
WO2026090357A1 (en) * 2024-10-24 2026-04-30 Adarx Pharmaceuticals, Inc. Mapt-modulating oligonucleotides for treating central nervous system diseases

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1948674A4 (en) * 2005-11-02 2009-02-04 Protiva Biotherapeutics Inc MODIFIED SIRNA MOLECULES AND APPLICATIONS THEREOF
GB0605337D0 (en) * 2006-03-17 2006-04-26 Genomica Sau Treatment of CNS conditions
CA2866392C (en) * 2012-03-30 2023-10-24 Washington University Methods for modulating tau expression for reducing seizure and modifying a neurodegenerative syndrome
US9133461B2 (en) * 2012-04-10 2015-09-15 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the ALAS1 gene
BR112015022156A2 (pt) * 2013-03-14 2017-11-14 Isis Pharmaceuticals Inc composições e métodos para modular a expressão de tau
US9951330B2 (en) * 2013-07-11 2018-04-24 The Trustees Of Columbia University In The City Of New York Micrornas that silence tau expression
TWI702046B (zh) * 2013-07-19 2020-08-21 美商Ionis製藥公司 用於調節τ蛋白表現之組合物
WO2015038892A1 (en) * 2013-09-13 2015-03-19 Moderna Therapeutics, Inc. Polynucleotide compositions containing amino acids
IL316808A (en) * 2014-08-20 2025-01-01 Alnylam Pharmaceuticals Inc Modified double-stranded RNA materials and their uses
CA2975525A1 (en) * 2015-02-04 2016-08-11 F. Hoffmann-La Roche Ag Tau antisense oligomers and uses thereof
ES2820713T3 (es) * 2015-03-25 2021-04-22 Univ Degli Studi Di Trento Terapia mediada por ARN interferente para enfermedades neurodegenerativas
CN117965536A (zh) * 2015-07-22 2024-05-03 波涛生命科学有限公司 寡核苷酸组合物及其方法
KR20250112919A (ko) * 2015-12-21 2025-07-24 노파르티스 아게 타우 발현을 감소시키기 위한 조성물 및 방법
JP7348185B2 (ja) * 2017-12-21 2023-09-20 アルニラム ファーマスーティカルズ インコーポレイテッド キラル富化二本鎖rna剤
TWI862501B (zh) * 2018-07-03 2024-11-21 瑞士商赫孚孟拉羅股份公司 用於調制 Tau 表現之寡核苷酸
CN115461085A (zh) * 2020-02-07 2022-12-09 生物欧赛加有限责任公司 miRNA-485抑制剂用于治疗tau蛋白病的用途
JP2023518439A (ja) * 2020-03-18 2023-05-01 ユニバーシティー オブ マサチューセッツ Mapt調節のためのオリゴヌクレオチド

Similar Documents

Publication Publication Date Title
JP7805386B2 (ja) Lpa発現を阻害するための組成物及び方法
JP2024536811A5 (cg-RX-API-DMAC7.html)
JP6343308B2 (ja) 筋緊張性ジストロフィー・プロテインキナーゼ(dmpk)発現の調整
JP6637442B2 (ja) 補体b因子発現を調節するための組成物及び方法
CN110042098B (zh) 用于调节hbv和ttr表达的组合物和方法
JP2022515193A5 (cg-RX-API-DMAC7.html)
TR201816256T4 (tr) Bir süjede smn2 uç birleştirmesinin modülasyonu için bileşimler ve yöntemler.
TWI924663B (zh) 用於抑制PNPLA3表現之RNAi劑、其醫藥組成物及使用方法
JP2023523993A5 (cg-RX-API-DMAC7.html)
US20190016748A1 (en) Compositions and methods for modulating angiopoietin-like 3 expression
JP2013526860A (ja) トランスサイレチン発現の調節
JP2017518045A (ja) Pkk発現を調節するための組成物及び方法
US20240240187A1 (en) Sirna targeting tmprss6 for the treatment of myeloproliferative disorders
JP2023511434A5 (cg-RX-API-DMAC7.html)
WO2018057575A1 (en) Myostatin irna compositions and methods of use thereof
JP2024528503A5 (cg-RX-API-DMAC7.html)
IL294728A (en) lrrk2 RNA material preparations and methods of using them
JP2025507372A5 (cg-RX-API-DMAC7.html)
JP2024522068A5 (cg-RX-API-DMAC7.html)
JP2024509783A5 (cg-RX-API-DMAC7.html)
US11634715B2 (en) Methods and compositions for treating bile duct paucity-associated conditions
JP2024521907A5 (cg-RX-API-DMAC7.html)
US20220186229A1 (en) Methods and compositions for inhibiting expression of cyp27a1
JP2025516321A5 (cg-RX-API-DMAC7.html)
RU2024111073A (ru) КОМПОЗИЦИИ АГЕНТА иРНК ПРОТИВ АССОЦИИРОВАННОГО С МИКРОТРУБОЧКАМИ ТАУ-БЕЛКА (MAPT) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ